Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 8/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3607652 | 0.83 | KDM4E (0.44) | ABL1KDM4EMAPK1HSD17B10NPC1 | |
| SCHEMBL3603808 | 0.83 | NPC1 (0.46) | ABL1KDM4EMAPK1HSD17B10NPC1 | |
| SCHEMBL3614585 | 0.83 | LMNA (0.40) | ABL1KDM4EMAPK1HSD17B10NPC1 | |
| SCHEMBL3612796 | 0.81 | PLAU (0.42) | KDM4EHSD17B10NPC1LMNATYR | |
| SCHEMBL3601750 | 0.81 | PIK3CG (0.46) | ABL1KDM4EMAPK1HSD17B10NPC1 | |
| SCHEMBL3612694 | 0.80 | MAPT (0.67) | ABL1KDM4EMAPK1HSD17B10NPC1 | |
| SCHEMBL10981488 | 0.80 | TYR (0.43) | ABL1KDM4EMAPK1HSD17B10NPC1 | |
| Bromide SCHEMBL10854264 | 0.80 | PLAU (0.41) | KDM4EHSD17B10NPC1LMNATYR | |
| SCHEMBL3612358 | 0.78 | AOC3 (0.57) | ABL1NPC1LMNAKMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL690838 | 0.77 | L3MBTL1 (0.66) | ABL1KDM4EMAPK1HSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | disclosed |
| EP-2010508-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | AstraZeneca AB (SE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2007120096-A1 | THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | WO | disclosed |
| US-4590299-A | 2-guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1986-05-20 | — | — | US | disclosed |
| US-4510313-A | 2-Guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1985-04-09 | — | — | US | disclosed |
| EP-0050458-B1 | 2-GUANIDINO-4-HETEROARYLTHIAZOLES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PFIZER INC. (US) | 1985-01-02 | — | — | EP | disclosed |
| US-4452987-A | Haloacetyl imidazoles | PFIZER INC. (US) | 1984-06-05 | — | — | US | disclosed |
| US-4374843-A | 2-Guanidino-4-heteroarylthiazoles | PFIZER INC. (US) | 1983-02-22 | — | — | US | disclosed |
| EP-0050458-A2 | 2-Guanidino-4-heteroarylthiazoles and pharmaceutical compositions containing them | PFIZER INC. (US) | 1982-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298340-A1 | Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies | GRN, MAPT, GUCY1B1 | ABL1 4507/4885KDM4E 4351/4885MAPK1 691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.